How the APOE ε4 Gene Influences Survival in Parkinson’s Disease

It’s well known that people with Parkinson’s disease generally live shorter lives than the average person. But why? Age, severity of symptoms, dementia and other factors play a part—but could our genes also influence how long we live with the disease? In a new study, researchers point a spotlight at one particular genetic variant, called APOE ε4, and suggest it may do more than we ever realised. The team mined data from the UK Biobank, a massive health and genetics database. They selected nearly 4,000 people of European descent diagnosed with Parkinson’s: 2,365 were still alive at the time of the study, and 1,575 had passed away. Importantly, in about 503 of these deaths Parkinson’s was the primary cause, and in 423 it was a secondary factor. The researchers used a statistical method called time-to-event (specifically a version of the Cox proportional hazards model) to scan the entire genome and identify variants linked to survival time. One variant stood out loud and clear—rs429358, the canonical marker for APOE ε4. Across all three analyses (Parkinson’s as the main cause of death, Parkinson’s as main or secondary cause, and all-cause mortality), carrying this variant was strongly tied to shorter survival. In plain English: Parkinson’s patients with this version of APOE tended to die earlier than those without it. The authors dug further. APOE ε4 is already famous for its role in Alzheimer’s and dementia risk. So, the question: is its effect on Parkinson’s survival just because people with ε4 get dementia more often? The data suggest not entirely. Yes, part of the effect seems mediated via dementia (in some analyses, about 19–51 % of the effect was explained this way), but APOE ε4 still showed a statistically significant effect independent of dementia status. In other words, even Parkinson’s patients without dementia who carry APOE ε4 seem to fare worse in terms of survival. To test mechanisms, the researchers turned to cell models. They engineered neuronal cells to express APOE ε2, ε3, or ε4 and subjected them to rotenone, a chemical known to trigger Parkinson’s-like stress in cells. Under this stress, cells expressing APOE ε4 fared worse: viability dropped, more DNA damage showed up, and markers of stress in the cell’s endoplasmic reticulum (ER) – a system critical for protein folding and stress response – were elevated. Mitochondrial function seemed impaired, too. Together, the genetic data and lab work tell a compelling story: APOE ε4 doesn’t just increase dementia risk—it may independently shorten life in Parkinson’s by making neurons more fragile, especially under disease stress. Still, the authors note limitations. The study focused on people of European ancestry, so findings may not generalise to other populations. The UK Biobank’s Parkinson’s diagnoses may lack some clinical depth compared to specialist PD cohorts. In their cell experiments, the presence of baseline APOE ε3 could muddy the clean isolation of APOE ε4’s effects. And, as always, what happens in a dish doesn’t prove exactly what happens in human brains. What this study adds is fascinating. APOE ε4 emerges not just as a dementia risk gene but also as a potential modulator of Parkinson’s progression and survival—even in people without dementia. That suggests new pathways to explore: why do ε4 carriers’ neurons give up sooner? Could therapies aimed at reducing ER stress or bolstering mitochondrial resilience help especially those people?